2026-05-21T23:19:46Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/172962024-11-28T15:08:19Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud author Torres, M J author Romano, A author Celik, G author Demoly, P author Khan, D A author Macy, E author Park, M author Blumenthal, K author Aberer, W author Castells, M author Barbaud, A author Mayorga, C author Bonadonna, P authoraffiliation [Torres,MJ; Mayorga,] Allergy Unit, National Network ARADyAL, IBIMA-Regional University Hospital of Malaga-UMA, Malaga, Spain. [Torres,MJ] BIONAND-Andalusian Centre for Nanomedicine and Biotechnology, Malaga, Spain. [Romano,A] Allergy Unit, Presidio Columbus, Rome, Italy. IRCCS Oasi Maria S.S., Troina, Italy. [Celik,G] Department of Chest Diseases, Division of Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey. [Demoly,P] Hôpital Arnaud de Villeneuve, University Hospital of Montpellier and Sorbonne Universités, UPMC Paris , IPLESP, Equipe EPAR, Paris, France. [Khan,DA] Department of Internal Medicine, Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA. [Macy,E] Kaiser Permanente Health Care Program, San Diego, CA, USA. [Park,M] Mayo Clinic College of Medicine, Division of Allergic Diseases, Mayo Clinic, Rochester, MN , USA. [Blumenthal,K] Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. [Aberer,W] Department of Dermatology, Medical University of Graz, Graz, Austria. [Castells,M] Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MSA, USA. [Barbaud,A] Sorbonne Universities, UPMC Univ Paris, Dermatology and Allergology Department, Tenon Hospital (AP-HP), Paris, France. [Allergy Unit, IBIMA-Regional University Hospital of Malaga-UMA (Pavilion C) Malaga, Spain. [Bonadonna,P] Allergy Unit, Azienda Ospedaliera Universitaria Intergrata of Verona, Verona, Italy. 2024-01-23T20:12:33Z 2024-01-23T20:12:33Z 2017-03-13 10.1186/s13601-017-0144-0 2045-7022 Clinical and Translational Allergy http://hdl.handle.net/10668/2681 28293415 http://hdl.handle.net/20.500.12105/17296 Drug hypersensitivity reactions (DHRs) affect an unknown proportion of the general population, and are an important public health problem due to their potential to cause life-threatening anaphylaxis and rare severe cutaneous allergic reactions. DHR evaluations are frequently needed in both ambulatory and hospital settings and have a complex diagnosis that requires a detailed clinical history and other tests that may include in vitro tests and in vivo procedures such as skin tests and drug provocation tests. Although over the years both European and U.S. experts have published statements on general procedures for evaluating DHRs, a substantial discordance in their daily management exists. In this review, we highlight both the differences and the similarities between the European and U.S. eng Drug Hypersensitivity Allergy Diagnosis Skin test In vitro test IgE T-cells Drug provocation test Sensitization Unit States Europe Anafilaxia Evaluación de Medicamentos Hipersensibilidad a las drogas Grupos étnicos Humanos Salud pública Pruebas cutáneas Estados Unidos Europa Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America research article